- BNF:
- 6.7.4
- Status:
- Red
- Decision Date:
- July 2017
Comments
Long term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again